<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737162</url>
  </required_header>
  <id_info>
    <org_study_id>china subclavian</org_study_id>
    <nct_id>NCT03737162</nct_id>
  </id_info>
  <brief_title>Bare-metal Stent vs Covered Stent in Chinese Patients With Subclavian Occlusive Lesions</brief_title>
  <acronym>BASELINE</acronym>
  <official_title>Bare-metal Stent vs Covered Stent in Chinese Patients With Subclavian Occlusive Lesions: Prospective, Multiple Center, Randomized, Open, Positive Controlled Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bare-metal stent vs Covered stent with subclavian occlusive lesions to verify the efficacy
      and safety.Study Design are prospective, multiple center, randomized, open, positive
      controlled, non-inferiority trail.Case total numbers enrollment predict 408 cases，each group
      204 cases.Follow up period for 1 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">July 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target lesion patency rate（%）</measure>
    <time_frame>1 years</time_frame>
    <description>12-month target lesion patency rate（%）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgery success rate</measure>
    <time_frame>1 day</time_frame>
    <description>Surgery success rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of complications within 30 days；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of myocardial infarction at 30 days follow up；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral stroke and death rates</measure>
    <time_frame>30 days</time_frame>
    <description>Ipsilateral stroke and death rates at 30 days follow up；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral stroke and death rates</measure>
    <time_frame>30 days</time_frame>
    <description>Bilateral stroke and death rates at 30 days follow up；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subclavian artery restenosis rate</measure>
    <time_frame>6、12 months</time_frame>
    <description>Subclavian artery restenosis rate at 6、12 months follow up；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite endpoints of myocardial infarction, stroke, and any death</measure>
    <time_frame>30days</time_frame>
    <description>Incidence of composite endpoints of myocardial infarction, stroke, and any death at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite endpoints of myocardial infarction, stroke, and any death</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of composite endpoints of myocardial infarction, stroke, and any death at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite endpoints of myocardial infarction, stroke, and any death</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of composite endpoints of myocardial infarction, stroke, and any death at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical time</measure>
    <time_frame>Through hospital stay，an average of 10 days</time_frame>
    <description>Surgical time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization days</measure>
    <time_frame>Through hospital stay，an average of 10 days</time_frame>
    <description>Hospitalization days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization fees</measure>
    <time_frame>Through hospital stay，an average of 10 days</time_frame>
    <description>Hospitalization fees</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Subclavian Occlusion</condition>
  <arm_group>
    <arm_group_label>Covered stent group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Covered stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bare-metal stent group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bare-metal stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stent implantation of subclavian artery</intervention_name>
    <description>Stent implantation of subclavian artery</description>
    <arm_group_label>Bare-metal stent group</arm_group_label>
    <arm_group_label>Covered stent group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≥50 years，sex unlimited；

          2. Left subclavian artery disease；

          3. The cause of clinical considerations is arteriosclerosis ；

          4. The presence of target organ ischemic symptoms, ie dizziness, headache, transient
             ischemic attack (TIA), stroke, or other related neurological symptoms caused by
             ischemia of the vertebral artery in the past 6 months, or the presence of arterial
             stenosis beyond the upper extremity limb ischemia symptoms subclavian；

          5. The patient understands the trial objective, understands and accepts the duration of
             the study，is able and willing to comply with all requirements，including follow-up and
             evaluation of it, voluntarily participates in the study and signs Informed Consent
             Form.

             Anatomy Criteria

          6. Subclavian artery independent disease（Do not merge carotid or vertebral artery disease
             ）；

          7. Subclavian artery satisfies one of the following criteria：

               1. a) Ultrasonography suggests stenosis ≥ 70%，or CT ANGIOGRAM / angiography showed
                  stenosis ≥ 70%；

               2. Iconography examination confirmed vertebral artery steals；

               3. Length of lesion is not involved in vertebral artery opening；

               4. Lesions in subclavian artery the beginning portion；

          8. The stent can reach the site of lesion smoothly as expected.

        Exclusion Criteria:

          1. Patients with anesthesia contraindications；

          2. Serious ipsilateral stroke occurred in the past and may confuse the judgment of the
             study endpoint ；

          3. Patients with severe dementia ；

          4. Patients with spontaneous intracerebral hemorrhage in the past 12 months ；

          5. Patients stroke episodes recently， CT or MRI suggested that the lesion is large，and
             may be with the risk of hemorrhagic transformation ；

          6. Large size of cerebral infarction or myocardial infarction occurred within 30 days ；

          7. Patients with large intracranial aneurysms (diameter&gt; 5mm)，and cannot be treated in
             advance or contemporaneous ；

          8. Chronic total occlusion without obvious cerebral ischemia symptoms ；

          9. Patients with hemorrhagic transformation of cerebral arterial thrombosis within 60
             days before surgery ；

         10. Hemoglobin &lt;100 g/l， Platelet count ＜125×109/L， INR＞1.5， Bleeding time &gt; 1
             min，patients with exceeding the upper limits of normal，or heparin-related
             thrombocytopenia ；

         11. Patients unable to perform normal angiographic evaluation or unsafe percutaneous
             puncture poin；

         12. Patients with neurologic disorder that caused transient or permanent neurological
             deficits within 2 years before the surgery and can not be identified with TIA or
             stroke ；

         13. Patients with other cardiac emboli sources, such as left ventricular aneurysm,
             intraluminal filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve,
             calcific aortic stenosis, infective endocarditis, mitral stenosis, atrial septal
             defect, atrial septal aneurysm, or left atrial myxoma；

         14. Surgical contraindications or patients with high risk of surgery defined as having any
             of the following；It is known that two or more proximal or main coronary artery
             stenosis ≥70%, untreated or unable to pass；Ejection fraction &lt;30% or New York Heart
             Association (NYHA) functional class III or higher；Unstable angina，ie angina at resting
             state and electrocardiogram changes；Currently waiting main organ transplants (ie
             heart, lung, liver, kidney), or are doing relevant evaluate；Malignant tumor or
             respiratory insufficiency, life expectancy &lt; 5 years or FORCED EXPIRATORY VOLUME AT
             ONE SECOND &lt; 30% (predicted)；Dialysis-dependent renal failure； Need to perform other
             general anesthesia during the same period ；

         15. There may be one or more anatomical conditions affecting the normal operative approach
             in patients； there may be one or more anatomic situations to increase the risk of
             adverse events in patients with high operative risk；including： Neck radiation therapy
             history； Radical neck surgery history；Subclavian artery dissection；Lesions
             series；Severe long segment calcification of the subclavian artery and severe stenosis
             or occlusion of the basilar artery；Inaccessible lesions by endoluminal methods (Severe
             distortion of the aortic arch branch, no suitable introduction of arteries, aortic
             arch anatomy special）；

         16. Investigators consider the patient inappropriate to participate in this clinical
             trial；

         17. Those who participated in clinical trials of other drugs or medical devices before the
             inclusion did not reach the end of the time limit.

         18. Rheumatic immune diseases, such as Takayasu arteritis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YongQuan Gu YQ Gu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YongQuan Gu YQ Gu, Prof.</last_name>
    <phone>+8615901598209</phone>
    <email>guyongquan@xwhosp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JianMing Guo JM Guo</last_name>
    <phone>+8613146369562</phone>
    <email>guojianming@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking hospital first University</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>YingHua Zou YH Zou, Prof.</last_name>
      <phone>+8613801105222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <zip>116000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Wang F Wang, Prof.</last_name>
      <phone>+8613998642840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ZhiQing Zhao ZQ Zhao, Prof.</last_name>
      <phone>+8613301617866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LeFeng Qu LF Qu, Prof.</last_name>
      <phone>+8618616505267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DaQiao Guo DQ Guo, Prof.</last_name>
      <phone>+8613801785258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital of Xi ' an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JianLin Liu JL Liu, Prof.</last_name>
      <phone>+8613709250539</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Yong-Quan Gu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

